A selective antibiotic for Lyme disease.
Animals
Anti-Bacterial Agents
/ therapeutic use
Borrelia burgdorferi
/ drug effects
Calibration
Cinnamates
/ chemistry
Drug Evaluation, Preclinical
Feces
/ microbiology
Female
HEK293 Cells
Hep G2 Cells
Humans
Hygromycin B
/ analogs & derivatives
Lyme Disease
/ drug therapy
Mice
Microbial Sensitivity Tests
Microbiota
/ drug effects
B. burgdorferi
Lyme disease
Spirochetes
antibiotic
microbiome
transport
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
14 10 2021
14 10 2021
Historique:
received:
28
04
2021
revised:
22
07
2021
accepted:
08
09
2021
pubmed:
8
10
2021
medline:
4
1
2022
entrez:
7
10
2021
Statut:
ppublish
Résumé
Lyme disease is on the rise. Caused by a spirochete Borreliella burgdorferi, it affects an estimated 500,000 people in the United States alone. The antibiotics currently used to treat Lyme disease are broad spectrum, damage the microbiome, and select for resistance in non-target bacteria. We therefore sought to identify a compound acting selectively against B. burgdorferi. A screen of soil micro-organisms revealed a compound highly selective against spirochetes, including B. burgdorferi. Unexpectedly, this compound was determined to be hygromycin A, a known antimicrobial produced by Streptomyces hygroscopicus. Hygromycin A targets the ribosomes and is taken up by B. burgdorferi, explaining its selectivity. Hygromycin A cleared the B. burgdorferi infection in mice, including animals that ingested the compound in a bait, and was less disruptive to the fecal microbiome than clinically relevant antibiotics. This selective antibiotic holds the promise of providing a better therapeutic for Lyme disease and eradicating it in the environment.
Identifiants
pubmed: 34619078
pii: S0092-8674(21)01058-8
doi: 10.1016/j.cell.2021.09.011
pmc: PMC8526400
mid: NIHMS1739885
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cinnamates
0
Hygromycin B
3XQ2233B0B
hygromycin A
3YJY415DDI
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5405-5418.e16Subventions
Organisme : NIAID NIH HHS
ID : R01 AI122286
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132836
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI141958
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152210
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests K.L. serves on the scientific advisory board of Flightpath.
Références
J Bacteriol. 2012 Jul;194(13):3336-42
pubmed: 22544267
J Antibiot (Tokyo). 1987 Nov;40(11):1619-26
pubmed: 3693130
Nat Methods. 2018 Oct;15(10):796-798
pubmed: 30275573
J Theor Biol. 2019 Feb 7;462:97-108
pubmed: 30419249
Infect Immun. 2003 Sep;71(9):5042-55
pubmed: 12933847
Nature. 2019 Dec;576(7787):459-464
pubmed: 31747680
Eur J Biochem. 1980 Jun;107(2):409-14
pubmed: 6156832
Science. 2015 Jun 5;348(6239):1106-12
pubmed: 26045430
Nat Rev Drug Discov. 2007 Jan;6(1):41-55
pubmed: 17159922
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32718967
Mol Membr Biol. 2004 Sep-Oct;21(5):323-36
pubmed: 15513740
J Clin Invest. 2014 Oct;124(10):4212-8
pubmed: 25271726
Ticks Tick Borne Dis. 2018 Sep;9(6):1464-1467
pubmed: 30007502
Infect Dis Clin North Am. 2015 Jun;29(2):309-23
pubmed: 25999226
Appl Environ Microbiol. 2009 Oct;75(20):6553-8
pubmed: 19700541
Cell. 2020 Apr 2;181(1):29-45
pubmed: 32197064
Appl Environ Microbiol. 2007 Mar;73(5):1501-13
pubmed: 17220265
Methods Mol Biol. 1995;47:253-9
pubmed: 7550741
Chem Biol. 2014 Apr 24;21(4):509-518
pubmed: 24684906
Infect Dis Clin North Am. 2008 Jun;22(2):341-60, vii-viii
pubmed: 18452806
J Neuroinflammation. 2018 Dec 19;15(1):346
pubmed: 30567544
Theor Biol Med Model. 2014 Nov 28;11:50
pubmed: 25432469
J Infect Dis. 2002 Nov 15;186(10):1430-7
pubmed: 12404158
Angew Chem Int Ed Engl. 2011 Jun 20;50(26):5889-91
pubmed: 21563281
Mol Syst Biol. 2006;2:2006.0008
pubmed: 16738554
Int J Infect Dis. 2013 Jun;17(6):e443-9
pubmed: 23462300
Infect Immun. 2015 Aug;83(8):3043-60
pubmed: 25987708
Nat Rev Microbiol. 2011 Apr;9(4):233-43
pubmed: 21358670
Infect Immun. 2003 Jun;71(6):3138-45
pubmed: 12761092
Antibiot Chemother (Northfield). 1953 Dec;3(12):1268-78
pubmed: 24542808
Biochem Pharmacol. 2017 Jun 15;134:114-126
pubmed: 27641814
Emerg Infect Dis. 2021;27(2):499-507
pubmed: 33496238
J Mol Microbiol Biotechnol. 2001 Jan;3(1):37-62
pubmed: 11200228
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30126963
Org Lett. 2012 Dec 7;14(23):5896-9
pubmed: 23148861
ISME J. 2012 Mar;6(3):610-8
pubmed: 22134646
mBio. 2020 Aug 4;11(4):
pubmed: 32753498
Int J Syst Evol Microbiol. 2003 May;53(Pt 3):815-821
pubmed: 12807206
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13865-70
pubmed: 11106398
Front Med (Lausanne). 2020 Feb 25;7:57
pubmed: 32161761
J Bacteriol. 1992 Jun;174(11):3757-65
pubmed: 1350586
Antimicrob Agents Chemother. 2010 Dec;54(12):5115-9
pubmed: 20837760
Nature. 2018 Oct;562(7728):589-594
pubmed: 30356183
Cell. 2014 Mar 27;157(1):121-41
pubmed: 24679531
Atherosclerosis. 2018 Apr;271:203-213
pubmed: 29524863
J Travel Med. 2020 Feb 3;27(1):
pubmed: 31840758
Mol Cell. 2015 Jun 4;58(5):832-44
pubmed: 26028538
mBio. 2020 Sep 29;11(5):
pubmed: 32994327
mBio. 2021 Feb 2;12(1):
pubmed: 33531385
Curr Protoc Microbiol. 2011 Feb;Chapter 12:Unit 12C.4
pubmed: 21400675
Infect Immun. 2006 Apr;74(4):2154-60
pubmed: 16552045
Front Med (Lausanne). 2017 Dec 14;4:224
pubmed: 29312942
Antimicrob Agents Chemother. 2013 Nov;57(11):5565-71
pubmed: 23979749
Am J Trop Med Hyg. 2011 Dec;85(6):1114-20
pubmed: 22144454
Mol Microbiol. 2015 Feb;95(3):509-38
pubmed: 25425211
mBio. 2015 Mar 17;6(2):e02481
pubmed: 25784704
Ann Agric Environ Med. 2002;9(1):111-3
pubmed: 12088407
J Microbiol Methods. 2011 Aug;86(2):243-7
pubmed: 21605603
Infect Immun. 2004 Dec;72(12):7147-54
pubmed: 15557639
Nat Microbiol. 2019 Apr;4(4):623-632
pubmed: 30718848
Antimicrob Agents Chemother. 2015 Aug;59(8):4616-24
pubmed: 26014929
Clin Vaccine Immunol. 2016 Sep 06;23(9):757-66
pubmed: 27358211
PLoS One. 2015 Feb 04;10(2):e0116767
pubmed: 25650808
Nucleic Acids Res. 2013 Aug;41(14):e144
pubmed: 23761439
Nucleic Acids Res. 2014 Jan;42(2):1245-56
pubmed: 24137004
Vector Borne Zoonotic Dis. 2006 Spring;6(1):103-12
pubmed: 16584333
PLoS Pathog. 2014 Jul 31;10(7):e1004238
pubmed: 25079227
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7372-7381
pubmed: 27697764
Mol Cell. 2008 Apr 25;30(2):190-202
pubmed: 18439898
Clin Infect Dis. 2012 Aug;55(3):343-50
pubmed: 22523260
Infect Immun. 2020 Mar 23;88(4):
pubmed: 31988175
Mol Microbiol. 2000 Jul;37(2):219-25
pubmed: 10931319
J Antibiot (Tokyo). 1997 Jun;50(6):514-21
pubmed: 9268009
Front Physiol. 2011 Dec 07;2:94
pubmed: 22162969
Nat Rev Dis Primers. 2016 Dec 15;2:16090
pubmed: 27976670
J Med Entomol. 1997 Nov;34(6):672-83
pubmed: 9439122
Immunol Lett. 2001 Feb 1;76(1):43-8
pubmed: 11222912
Nature. 2015 Jan 22;517(7535):455-9
pubmed: 25561178
Clin Infect Dis. 2014 Feb;58(3):372-80
pubmed: 24218102
mBio. 2018 Jun 26;9(3):
pubmed: 29946052
J Bacteriol. 1995 Jul;177(14):4121-30
pubmed: 7608087
Lancet. 2021 Mar 13;397(10278):967-968
pubmed: 33684352